Dr. Reddy's Laboratories, Ltd.

Dr. Reddy's Laboratories Ltd. — commonly "Dr. Reddy's" — is an Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana, India (8-2-337, Road No. 3, Banjara Hills). It was founded in 1984 by Dr. K. Anji Reddy. The company is publicly listed on the Bombay Stock Exchange and National Stock Exchange of India (ticker DRREDDY) and has ADSs traded on the NYSE (RDY). It reports roughly 27,000+ employees worldwide and FY2025 revenue of about ₹325 billion (approximately US$3.8 billion), per FT and company filings.

Products and operations. Dr. Reddy's is an integrated generics-led pharmaceutical manufacturer. Its largest segment, Global Generics, covers prescription and over-the-counter finished dosages sold as generics and branded formulations across the U.S., India, Russia/CIS, Europe, and other emerging markets. Its Pharmaceutical Services and Active Ingredients (PSAI) segment manufactures and supplies active pharmaceutical ingredients and intermediates, and the company is expanding CDMO services through Aurigene Pharmaceutical Services. Growth areas include biosimilars (e.g., denosumab, rituximab, abatacept, and a partnered pembrolizumab candidate), GLP-1/peptide products, oncology through subsidiary Aurigene Oncology, and a consumer-health/NRT portfolio acquired from Haleon (Nicotinell). It operates numerous formulation, API, and biologics plants plus R&D centers.

Litigation posture. The structured data shows one tracked case, in which Dr. Reddy's is a defendant (0 as plaintiff, 1 as defendant). This is the profile of an operating company being sued, not a patent assertion entity. The single suit sits in the U.S. District Court for the District of Delaware, a common venue for pharmaceutical patent disputes, rather than a plaintiff-friendly Texas venue.

Notable case. Merck Sharp & Dohme Corp. v. Dr. Reddy's Laboratories Ltd. et al. (D. Del.) is the sole tracked matter, naming Dr. Reddy's as a defendant. The case data does not specify the product or patent at issue. Consistent with the company's generics business, such suits typically arise from Hatch-Waxman/ANDA patent challenges, but the specific subject matter should be confirmed from the docket; it is not established by the data provided.